NUDT15 and inflammatory bowel disease: Mirroring the recommendations based on TPMT genotyping for nonmalignant conditions such as IBD, PMs of NUDT15 are recommended to consider nonthiopurine immunosuppressant therapy, while IMs would benefit from a reduction of the standard starting dose.